Kine Sciences Co., Ltd.

This early study tested a new drug called KINE-101 in 9 adults with a rare nerve disease (CIDP) that did not improve with standard steroid treatment. The main goal was to check if a single dose of the drug is safe and tolerable. Researchers monitored participants for 28 days afte…

This early-stage study tested the safety of a new drug called KINE-101 in 24 healthy adults. Participants received daily intravenous doses for a week at different strength levels. The goal was to see if the drug is safe and how the body processes it, not to treat any disease.

This early-stage study tested a new drug called KINE-101 in 40 healthy adults to see if it is safe and how the body processes it. Participants received either the drug or a placebo as a single dose through an IV or injection. The study is complete and provides important safety in…